The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $115.17

Today's change+0.48 +0.42%
Updated July 24 4:02 PM EDT. Delayed by at least 15 minutes.
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $115.17

Today's change+0.48 +0.42%
Updated July 24 4:02 PM EDT. Delayed by at least 15 minutes.

Taro Pharmaceutical Industries Ltd crosses above 20-day moving average

Taro Pharmaceutical Industries Ltd closed up Monday by (U.S.)$0.48 or 0.42% to (U.S.)$115.17 and crossing above its 20-day moving average. Over the last five days, shares have gained 0.79% and 9.40% year to date. Shares have underperformed the S&P 500 by 34.10% during the last year.

Key company metrics

  • Open(U.S.) $114.62
  • Previous close(U.S.) $114.69
  • High(U.S.) $115.68
  • Low(U.S.) $113.16
  • Bid / Ask-- / --
  • YTD % change+9.40%
  • Volume62,970
  • Average volume (10-day)83,510
  • Average volume (1-month)67,525
  • Average volume (3-month)71,852
  • 52-week range(U.S.) $92.28 to (U.S.) $146.89
  • Beta0.64
  • Trailing P/E10.42×
  • P/E 1 year forward12.08×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $11.05
Updated July 24 4:02 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+51.97%

Based on its net profit margin of 51.97%, Taro Pharmaceutical Industries Ltd is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.36%Sector:HealthcareIndustry:Pharmaceuticals - Diversified

Latest Company News

View more News
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2017Q3/2017Q2/2017Q1/2017
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue196220229234
Total other revenue--------
Total revenue196220229234
Gross profit144167177183
Total cost of revenue52535151
Total operating expense95918791
Selling / general / administrative22202122
Research & development20181518
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0000
Other operating expenses, total--------
Operating income102129142143
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax100161160140
Income after tax83140124110
Income tax, total17203630
Net income83140124110
Total adjustments to net income--------
Net income before extra. items83140124110
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items83140124110
Inc. avail. to common incl. extra. items83140124110
Diluted net income83140124110
Dilution adjustment--------
Diluted weighted average shares41414142
Diluted EPS excluding extraordinary itemsvalue per share2.053.423.002.60
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share2.053.423.002.60